Why the study?
Is there an association between clinicopathological features and TAFI, TFPI, and prothrombin fragment 1+2 levels in patients with advanced colorectal cancer?
Is there an association between clinicopathological features and TAFI, TFPI, and prothrombin fragment 1+2 levels in patients with advanced colorectal cancer?
Answers are grounded in this paper and cite their sources.
Observed associations in advanced colorectal cancer warrant caution; leaves open prognostic utility pending validation.
Giri ve Ama: Tromboembolizm kanser hastalarnda yaygn olarak grlmektedir. Kolorektal kanser geliimi ve progresyonu srasnda koaglasyon ve fibrinolitik sistemdeki pek ok molekl aktive olmaktadr.Trombinle aktive fibrinolizis inhibitr (TAFI), doku faktr yolak inhibitr (TFPI) ve protrombin fragmant 1+2 koaglasyon ve fibrinoliziste yeni tanmlanan molekllerdir.
No takes yet. Share an insight, caveat, or question.
Salman et al. (2016) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: